SBIR and STTR Success Story for
Organix, Inc.

(Information Posted/Updated on 05/10/2012)

Organix, Inc.
240 Salem Street
Woburn, MA  01801

Contact:    Howard Sard
Phone:      781-932-4142
Fax:          781-933-6695
Web Site:

Project Title:  Indole Analogs as Novel Treatments for OCD
Related Award(s):  R43MH063529; R44MH063529
Technology Developed:
Novel serotonin 5-HT2C-selective agonists were discovered and developed. These novel compounds were studied in vitro and in vivo and are promising leads for the treatment of OCD, other CNS disorders, and appetite suppression.

Key Words:  serotonin, obesity, 5-HT2C receptor, OCD.
Uses of Technology/Products/Service:
We have discovered potential new drugs for the treatment of many diseases. Together with others, we are continuing research to further study of these new drugs. If this research is ultimately successful, a new pharmaceutical will be approved by the FDA and will be of great benefit to human health.

Benefit to Company:
We have been able to hire additional research staff to carry out work on these SBIR grants. We have also benefited through a licensing agreement signed with Galenea Corporation of Cambridge, MA which was based on the work carried out under these SBIR grants. This agreement involves licensing and royalty payments.

How Product Was Commercialized:
The intellectual property developed through these SBIR grants was licensed in 2008 to Galenea Corporation of Cambridge, MA.

Other Comments Related to Company's Success Story:
We are grateful for the support from NIMH and NIDDK without which we would never have been able to accomplish our research and development goals.

Past R&D and/or Sales from this Project:   $NA
Estimated Future Annual R&D and/or Sales from this Project:   $unknown